BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats

European Journal of Pharmacology

Volumn 647, Issue 1-3, 2010, Pages 147-154

  Thorsen, Lise Bech ^a   Eskildsen Helmond, Yvonne ^a   Zibrandtsen, Helle ^a   Stasch, Johannes Peter ^b   Simonsen, Ulf ^a   Laursen, Britt Elmedal ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b BAYER PHARMA AG   (Germany)

Author keywords

BAY 41 2272; Hypoxia; Nitric oxide; Pulmonary hypertension

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; DRINKING WATER; GUANYLATE CYCLASE; OUABAIN; SILDENAFIL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENZYME LOCALIZATION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOBARISM; HYPOXIA; IMMUNOBLOTTING; LUNG RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASODILATATION;

ANIMALS; ANOXIA; CELL ADHESION MOLECULES; GUANYLATE CYCLASE; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PIPERAZINES; PULMONARY ARTERY; PURINES; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; SULFONES; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 77957322681     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.032     Document Type: Article

References (27)

1. Andersen C.U., Mulvany M.J., Simonsen U. Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. Eur. J. Pharmacol. 2005, 510:87-96.
2. Bawankule D.U., Sathishkumar K., Sardar K.K., Chanda D., Krishna A.V., Prakash V.R., Mishra S.K. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3, 4-b]pyridine-3-yl]pyri midin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump. J. Pharmacol. Exp. Ther. 2005, 314:207-213.
3. Cau S.B., Dias-Junior C.A., Montenegro M.F., de Nucci G., Antunes E., Tanus-Santos J.E. Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. Eur. J. Pharmacol. 2008, 581:132-137.
4. Deruelle P., Grover T.R., Abman S.H. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L798-L806.
5. Deruelle P., Balasubramaniam V., Kunig A.M., Seedorf G.J., Markham N.E., Abman S.H. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol. Neonate 2006, 90:135-144.
6. Dumitrascu R., Weissmann N., Ghofrani H.A., Dony E., Beuerlein K., Schmidt H., Stasch J.P., Gnoth M.J., Seeger W., Grimminger F., Schermuly R.T. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006, 113:286-295.
7. Elmedal B., de Dam M.Y., Mulvany M.J., Simonsen U. The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats. Br. J. Pharmacol. 2004, 141:105-113.
8. Elmedal L.B., Mulvany M.J., Simonsen U. Involvement of guanylyl cyclase, protein kinase A and Na+K+ATPase in relaxations of bovine isolated bronchioles induced by GEA 3175, an NO donor. Pulm. Pharmacol. Ther. 2006, 19:179-188.
9. Evgenov O.V., Ichinose F., Evgenov N.V., Gnoth M.J., Falkowski G.E., Chang Y., Bloch K.D., Zapol W.M. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004, 110:2253-2259.
10. Evgenov O.V., Kohane D.S., Bloch K.D., Stasch J.P., Volpato G.P., Bellas E., Evgenov N.V., Buys E.S., Gnoth M.J., Graveline A.R., Liu R., Hess D.R., Langer R., Zapol W.M. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am. J. Respir. Crit. Care Med. 2007, 176:1138-1145.
11. Faro R., Moreno L., Hislop A.A., Sturton G., Mitchell J.A. Pulmonary endothelium dependent vasodilation emerges after birth in mice. Eur. J. Pharmacol. 2007, 567:240-244.
12. Hassoun P.M., Filippov G., Fogel M., Donaldson C., Kayyali U.S., Shimoda L.A., Bloch K.D. Hypoxia decreases expression of soluble guanylate cyclase in cultured rat pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 2004, 30:908-913.
13. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2004, 351:1425-1436.
14. Kanthapillai P., Lasserson T., Walters E. Sildenafil for pulmonary hypertension. Cochrane Database Syst. Rev. 2004, CD003562.
15. Koglin M., Stasch J.P., Behrends S. BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase. Biochem. Biophys. Res. Commun. 2002, 292:1057-1062.
16. Li D., Laubach V.E., Johns R.A. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L369-L376.
17. McNamara P.J., Murthy P., Kantores C., Teixeira L., Engelberts D., van V.T., Kavanagh B.P., Jankov R.P. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L205-L213.
18. Moreno L., Gonzalez-Luis G., Cogolludo A., Lodi F., Lopez-Farre A., Tamargo J., Villamor E., Perez-Vizcaino F. Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L125-L130.
19. Mulvany M.J., Halpern W. Mechanical properties of vascular smooth muscle cells in situ. Nature 1976, 260:617-619.
20. Ostergaard L., Stankevicius E., Andersen M.R., Eskildsen-Helmond Y., Ledet T., Mulvany M.J., Simonsen U. Diminished NO release in chronic hypoxic human endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H2894-H2903.
21. Reinhard M., Halbrugge M., Scheer U., Wiegand C., Jockusch B.M., Walter U. The 46/50kDa phosphoprotein VASP purified from human platelets is a novel protein associated with actin filaments and focal contacts. EMBO J. 1992, 11:2063-2070.
22. Schafer A., Burkhardt M., Vollkommer T., Bauersachs J., Munzel T., Walter U., Smolenski A. Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem. Pharmacol. 2003, 65:397-405.
23. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Yilmaz H., Butrous G., Ermert L., Ermert M., Weissmann N., Rose F., Guenther A., Walmrath D., Seeger W., Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 2004, 169:39-45.
24. Schermuly R.T., Stasch J.P., Pullamsetti S.S., Middendorff R., Muller D., Schluter K.D., Dingendorf A., Hackemack S., Kolosionek E., Kaulen C., Dumitrascu R., Weissmann N., Mittendorf J., Klepetko W., Seeger W., Ghofrani H.A., Grimminger F. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J. 2008, 32:881-891.
25. Sebkhi A., Strange J.W., Phillips S.C., Wharton J., Wilkins M.R. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003, 107:3230-3235.
26. Stasch J.P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schroder H., Schroeder W., Stahl E., Steinke W., Straub A., Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001, 410:212-215.
27. Walker D.K., Ackland M.J., James G.C., Muirhead G.J., Rance D.J., Wastall P., Wright P.A. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999, 29:297-310.